Small molecule metabolites: discovery of biomarkers and therapeutic targets [0.03%]
小分子代谢物：生物标志物和治疗靶点的发现
Shi Qiu,Ying Cai,Hong Yao et al.
Shi Qiu et al.
Metabolic abnormalities lead to the dysfunction of metabolic pathways and metabolite accumulation or deficiency which is well-recognized hallmarks of diseases. Metabolite signatures that have close proximity to subject's phenotypic informat...
Structural characteristics of the SARS-CoV-2 Omicron lineages BA.1 and BA.2 virions [0.03%]
SARS-CoV-2奥密克戎谱系BA.1和BA.2病毒颗粒的结构特征
Xiaoyu Ma,Yanqun Wang,Yuanzhu Gao et al.
Xiaoyu Ma et al.
Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer [0.03%]
吡咯替尼加上替比放可在HER2阳性转移性乳腺癌的二线治疗中显著改善总生存期
Xiuwen Guan,Fei Ma,Qiao Li et al.
Xiuwen Guan et al.
ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression [0.03%]
ALYREF介导RNA m5C修饰以促进肝癌进展
Chen Xue,Xinyu Gu,Qiuxian Zheng et al.
Chen Xue et al.
Rongshuang Huang,Ping Fu,Liang Ma
Rongshuang Huang
Chronic kidney disease (CKD) is estimated to affect 10-14% of global population. Kidney fibrosis, characterized by excessive extracellular matrix deposition leading to scarring, is a hallmark manifestation in different progressive CKD; Howe...
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study [0.03%]
特瑞普利单抗联合仑伐替尼和吉玛疗治疗晚期肝内胆管癌：一项一期临床试验
Guo-Ming Shi,Xiao-Yong Huang,Dong Wu et al.
Guo-Ming Shi et al.
Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC. Thirty pat...
A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants [0.03%]
具有较强抗SARS-CoV-2奥密克戎变异株活性的新一代Mpro抑制剂
Chong Huang,Huiping Shuai,Jingxin Qiao et al.
Chong Huang et al.
Emerging SARS-CoV-2 variants, particularly the Omicron variant and its sublineages, continually threaten the global public health. Small molecule antivirals are an effective treatment strategy to fight against the virus. However, the first-...
Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2 [0.03%]
SARS-CoV-2奥密克戎亚变体XBB.1.5、BQ.1、BQ.1.1、BF.7和BA.2.75.2的抗原表征
Airu Zhu,Peilan Wei,Miao Man et al.
Airu Zhu et al.
Engineered exosomes from different sources for cancer-targeted therapy [0.03%]
来源于不同途径的工程化外泌体用于癌症靶向治疗
Menghui Zhang,Shengyun Hu,Lin Liu et al.
Menghui Zhang et al.
Exosome is a subgroup of extracellular vesicles, which has been serving as an efficient therapeutic tool for various diseases. Engineered exosomes are the sort of exosomes modified with surface decoration and internal therapeutic molecules....
Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine [0.03%]
单剂Ad5-nCoV疫苗有效清除持续性新冠病毒无症状感染
Shaofu Qiu,Zhao Chen,Airu Zhu et al.
Shaofu Qiu et al.
Persistent asymptomatic (PA) SARS-CoV-2 infections have been identified. The immune responses in these patients are unclear, and the development of effective treatments for these patients is needed. Here, we report a cohort of 23 PA cases c...